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Michael A. Pulsipher8INTRODUCTION
On April 28-29, 2011, a conference titled, ‘‘Late
Effects after Pediatric Hematopoietic Cell Transplan-
tation: State of the Science, Future Directions’’ was
held in Arlington, VA, with a goal of bringing together
leaders in the field of pediatric transplantation survi-
vorship to review the current state of knowledge and
define gaps in the field, develop consensus on critical
areas for future research, and determine the best study
designs to effectively address these questions. Over the
course of the next several months, 6 summary articles
covering the major topics discussed at the conference
will be published in this journal, which will define
and set forth recommendations for a research agenda
to move this field forward over the next decade.
Study of late effects after pediatric hematopoietic
cell transplantation (HCT) offers unique opportuni-
ties and challenges. The opportunities include an
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addition, these individuals have decades of life ahead
of them, with potentially new issues arising as they
age. The challenges, however, are daunting. The num-
bers of transplantations for any given condition are few,
with even the largest centers performing only a handful
of transplants for a given condition each year. This is-
sue ismagnified by the fact that children going through
each developmental stage (infant, toddler, child pread-
olescent, and young adult) have different sensitivities
to therapies, resulting in different complications (ie, in-
fants and toddlers are susceptible to neurocognitive
damage with radiation, and adolescents are at high
risk of joint/bone issues with steroid therapy). Further-
more, the ability to self-report symptoms changes
throughout the continuumof transplantation survivor-
ship, both across different patients and even within
eachpatient.Thus, to bemost effective, the studyof pe-
diatric late effects after HCT in children should ideally
occur in a multi-institutional setting to maximize ac-
crual. To date, such efforts have been limited.
Over the last few years, cooperative groups in
North America involving pediatric HCT have
strengthened and assembled the expertise and infra-
structure to start to address these issues. The NCI/
NHLBI Bone Marrow Transplant Clinical Trials
Network (BMTCTN) has successfully executed com-
bined adult/pediatric and pediatric-only therapeutic
trials, and has an active Pediatric Diseases Committee.
The StemCell Committee of the Children’s Oncology
Group (COG) has formed a cooperative agreement
with the Pediatric Blood and Marrow Transplant
Consortium (PBMTC), initiating several phase II
and III trials. The PBMTC has further allied with
the clinical trials arm of the Center of International
Blood and Marrow Transplant Research (CIBMTR)
to run PBMTC pilot trials that will lead to larger trials
in COG or the BMT CTN. Cooperative efforts be-
tween these groups have resulted in 3 phase III trials,
3 phase II, and 1 large minimal residual disease
(MRD) biomarker trial, which is currently under
Figure 1. All-cause mortality in a cohort of 1479 21-year survivors
after allogeneic HCT. This research was originally published in Blood.
Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic
hematopoietic cell transplantation and functional status of long-term
survivors: report from the Bone Marrow Transplant Survivor Study.
Blood. 2007;110:3784-3792. Q the American Society of Hematology.
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pliant, and the infrastructure, expertise, and personnel
are increasingly ready to tackle challenging late effects
trials.
Given these issues and opportunities, a consensus
conference was organized with the aim of defining
the most critical questions in this understudied field.
The goals of this conference were 3-fold: (1) define
methodologic challenges in studying long-term out-
comes after HCT including the impact of pretrans-
plantation therapies/complications and post-HCT
events on late effects in survivors who underwent
HCT as children; (2) discussmethodologies that incor-
porate the identification of biomarkers of adverse out-
comes and also how the role of genetic predisposition
to certain adverse events and/or late effects can be asso-
ciated with exposure to specific chemotherapeutic
agents or radiation; and (3) review selected high-risk
organ systems, persistent immunodeficiency, issues of
tolerance, neurocognitive outcomes, and health-
related quality of life (HR-QOL) outcomes in survivors
after HCT during childhood in order to determine
high-impact questions for multi-institutional trials.Significance: The Lifetime Impact of
Posttransplantation Late Effects
Expansion of the number of indications for trans-
plantation and improvements in the availability of
appropriate alternative donor stem cell sources to pa-
tients with rare HLA types through the use of cord
blood and haploidentical approaches has resulted in
increased numbers of HCT performed in children
annually. In conjunction with this, a reduction in the
mortality secondary to relapse, infections, graft-versus-
host disease (GVHD), and other acute transplant-
related complications [1] is leading to improved survival
rates and thus an ever-increasing population of
HCT survivors.
As we continue to followHCT patients in the long
term, however, we are finding that in both the autolo-
gous as well as the allogeneic transplant setting, HCT
survivors experience mortality rates higher than the
general population [2,3]. One of the largest and most
comprehensive studies of HCT survivors to date, the
Bone Marrow Transplant Survivor Study (BMT-SS),
examined patients treated with HCT who were alive
at least 2 years posttransplant and found that
allogeneic HCT survivors were at a 9.9-fold-increased
risk of premature death (Figure 1). Even 15 years after
transplantation, these patients continued to have mor-
tality rates twice that of the general population (stan-
dardized mortality ratio 5 2.2). Although relapse of
the primary disease and chronic GVHD (cGHVD)
were the leading causes of death, late mortality was
attributed to treatment-related causes in 25% of
deaths including second malignancies, late infections,and cardiac and pulmonary causes. Similar findings
were recently published from the Seattle group where
mortality rates in patients who survived for more than
5 years after HCT were 4- to 9-fold higher than the
general population for at least 30 years after transplan-
tation [4]. In this analysis, secondmalignancies, late in-
fections, cardiovascular or other vascular causes, and
pulmonary complications were again the most fre-
quent causes of mortality. This resulted in an absolute
decrease in estimated residual life expectancy of 17.0
years for survivors at 20 years of age to 6.4 years for
survivors at 60 years of age (Figure 2A), and a propor-
tionate reduction in life expectancy of approximately
30% regardless of attained age (Figure 2B). In both
of these studies, it was difficult to discern the relative
contribution of pretransplantation therapy to the risk
of cardiovascular-related death, as similar data has
been reported in survivors of childhood cancer who
have not undergone HCT as part of their therapy
where the risk of nonrelapse death in patients surviving
for 5 years or more was 8-fold higher than the U.S.
population [5].
Although the issue of premature mortality is of
obvious concern, the overall and cumulative impact
of late effects in HCT survivors is also alarming.
Large, comprehensive studies have shown in detail
the burden of late effects in childhood cancer survi-
vors. In 2 seminal studies, with a median follow-up
of 25 and 17 years, the cumulative incidence of late
effects after childhood cancer was 73% and 75%, res-
pectively [6,7]. In both studies, over 40% of survivors
had severe, disabling and/or life-threatening late effects
or died because of an adverse effect of cancer treatment.
One of these studies was a multi-institutional effort
by the Childhood Cancer Survivor Study (CCSS).
This and many other efforts of the CCSS have created
significant expertise regarding these issues in the pedi-
atric cancer research community; however, the CCSS
contains only a very small number of HCT survivors
Figure 2. Projected reduction in life expectancy in the study cohort
relative to U.S. population data as a function of attained age. (A) Abso-
lute reduction in years; (B) percentage reduction. This research was
originally published in Martin PJ, Counts GW Jr., Appelbaum FR, et al.
Life expectancy in patients surviving more than 5 years after hematopoi-
etic cell transplantation. J Clin Oncol. 2010;28:1011-1016.
1426 Biol Blood Marrow Transplant 17:1424-1427, 2011K. S. Baker et al.and was not designed to look specifically at HCT-
related issues.
A handful of single-center studies describe the
cumulative incidence and severity of late effects in sur-
vivors of childhood HCT [8-12]. Most of these studies
focused on survivors with a particular disease, age, and/
or conditioning regimen (eg, including total body irri-
diation [TBI]) and described the cumulative incidence
of specific late effects separately. Only 1 study assessed
comprehensively the burden of late effects according to
Common Terminology Criteria for Adverse Events
(CTCAE version 3.0). Pediatric HCT survivors had
a higher cumulative incidence of late effects compared
with the studies of cancer survivors who did not receive
HCT as part of their treatment, with 93% of survivors
having at least 1 late effect with a median follow-up of
only 7 years. In contrast, only 25% of pediatric HCT
survivors had severe or disabling/life-threatening late
effects [12], but the follow-up was 1 to 2 decades less
than the childhood cancer studies.
Much remains to be learned by multicenter studies
with longer follow-up; however, the experience gained
through studies in pediatric cancer survivors, alongwith experience gained at centers studying late effects
in adult HCT recipients, has shaped a group of
researchers capable of performing these studies.
With expertise and infrastructure now available to
allow this field to move into high-quality multicenter
studies, the next step is obvious: We must define the
best questions, approach them with the most innova-
tive and informative methodologies, and come to
a consensus about how to prioritize the work and
move forward.Postconference Proceedings
Over the course of the next several months (and
starting with this current issue of the BBMT), a series
of papers will be published on topics considered to be
the most critical for future research efforts. These in-
clude:
1. Etiology and Pathogenesis of Late Effects after
HSCT Performed in Childhood—Methodological
Challenges
2. Allogeneic Immune Reconstitution and Tolerance
in Children after HCT
3. Organ Toxicities and Metabolism
4. Quality of Life, Functional, and Neurocognitive
Outcomes
5. Endocrine Challenges: Thyroid Dysfunction,
Growth Impairment, Bone Health, and Reproduc-
tive Risks
6. Consensus Guidelines for Long-Term Follow-Up
after Pediatric HCT
Each of these papers will describe the current state
of knowledge as well as what the gaps are in this cur-
rent knowledge. In addition, there will be a description
of what preliminary or emerging new data (clinical or
preclinical, animal models, etc.) and what new
research is being done (which may or may not be fo-
cused directly on HCT populations) that sets the stage
or direction for where research in that particular area
needs to move in the future. Where relevant, there
will be a discussion on what would be appropriate
screening and management recommendations from
a clinical standpoint for HCT survivors. Finally, the
authors will summarize, based on their presentations
and conference discussions, what the recommenda-
tions are for future research (ie, What are the highest
priority questions to be answered and how should
studies be designed to answer these questions?).
Our hope is that these publications will stimulate
further interest and discussion surrounding each of
these very important topics and that investigators
from a variety of disciplines will come together to
formulate study questions, grant submissions, and pro-
tocols that will begin to provide clinically useful
knowledge that can be applied to the long-term
follow-up care of pediatric HCT survivors. The
Biol Blood Marrow Transplant 17:1424-1427, 2011 1427NCI, NHLBI First International Consensus Conferenceultimate goal of future studies will be to modify
HCT approaches, systematize post-HCT late effects
screening, and improve management of late effects
in a manner that reduces long-term morbidity and
improves the quality and length of pediatric HCT
survivors’ lives.ACKNOWLEDGMENTS
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